Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The mitochondrial ribosome small subunit (28S) is a specialized ribonucleoprotein complex essential for the translation of the 13 polypeptides encoded by mitochondrial DNA (mtDNA) (Greber & Ban, 2016, Annual Review of Biochemistry). These proteins are core components of the oxidative phosphorylation (OXPHOS) machinery, making the small subunit indispensable for cellular energy production (Amunts et al., 2015, Science). Structurally, it is composed of the 12S ribosomal RNA and approximately 30 mitoribosomal proteins (MRPS) (UniProt, 2024). Due to its evolutionary descent from alphaproteobacteria, the 28S subunit shares significant structural homology with the bacterial 30S ribosome, which explains the off-target toxicity of certain antibiotics like tetracyclines and aminoglycosides (Guan et al., 2000, Human Molecular Genetics). In clinical research, this subunit is being investigated as a therapeutic target in oncology, as many cancer cells rely on upregulated mitochondrial biogenesis for survival and metastasis (Lamb et al., 2015, Oncotarget). Mutations in the genes encoding the 28S subunit components are associated with severe clinical phenotypes, including Leigh syndrome and sensorineural hearing loss (PubMed, 2022).
Inhibition of mitochondrial protein synthesis by binding to the 28S subunit, which interferes with the binding of aminoacyl-tRNA to the ribosomal A-site or induces translational misreading (PubMed, 2023).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial ribosome small subunit (28S subunit).